Published : 10 May 2011
A World leading company in the discovery and development of fully-human antibody therapeutics today signed up with Aagami to finding them the licensing partner for their lead molecules as well as anti body discovery technologies for a wide range of diseases, including cancer.
Company has a powerful suite of antibody technologies, including the ability to discover fully-human antibodies to inhibit G-Protein Coupled Receptors. In addition, it is building an impressive pipeline of fully-human antibody products, initially focused on cancer. Company is seeking to license both its technologies and its products into the Indian market.
The company has already established high-value partnerships with biotechnology and pharmaceutical companies in Europe and with a number of world-renowned academic institutes.